Nita A Limdi1, Thomas D Nolin2, Sarah L Booth3, Amanda Centi3, Marisa B Marques4, Michael R Crowley5, Michael Allon6, T Mark Beasley7. 1. Neurology, University of Alabama at Birmingham, Birmingham, AL. Electronic address: nlimdi@uab.edu. 2. Pharmacy and Therapeutics, Jean Mayer USDA Human Nutrition Research Center on Aging, School of Pharmacy, University of Pittsburgh, Pittsburgh, PA. 3. Vitamin K Laboratory, Jean Mayer USDA Human Nutrition Research Center on Aging, School of Pharmacy, University of Pittsburgh, Pittsburgh, PA. 4. Pathology, Section on Statistical Genetics, University of Alabama at Birmingham, Birmingham, AL. 5. Genetics, Section on Statistical Genetics, University of Alabama at Birmingham, Birmingham, AL. 6. Division of Nephrology, Medicine, Section on Statistical Genetics, University of Alabama at Birmingham, Birmingham, AL. 7. Biostatistics, Section on Statistical Genetics, University of Alabama at Birmingham, Birmingham, AL.
Abstract
BACKGROUND: Anticoagulation management is difficult in chronic kidney disease, with frequent supratherapeutic international normalized ratios (INRs ≥ 4) increasing hemorrhagic risk. We evaluated whether the interaction of INR and lower estimated glomerular filtration rate (eGFR) increases hemorrhage risk and whether patients with lower eGFRs experience slower anticoagulation reversal. STUDY DESIGN: Prospective cohort study. SETTING & PARTICIPANTS: Warfarin pharmacogenetics cohort (1,273 long-term warfarin users); warfarin reversal cohort (74 warfarin users admitted with INRs ≥ 4). PREDICTOR: eGFR, INR as time-dependent covariate, and their interaction in the pharmacogenetics cohort; eGFR in the reversal cohort. OUTCOMES & MEASUREMENTS: In the pharmacogenetics cohort, hemorrhagic (serious, life-threatening, and fatal bleeding) risk was assessed using proportional hazards regression. In the reversal cohort, anticoagulation reversal was assessed from changes in INR, warfarin and metabolite concentrations, clotting factors (II, VII, IX, and X), and PIVKA-II (protein induced by vitamin K absence or antagonist II) levels at presentation and after reversal, using linear regression and path analysis. RESULTS: In the pharmacogenetics cohort, 454 (35.7%) had eGFRs < 60 mL/min/1.73 m(2). There were 137 hemorrhages in 119 patients over 1,802 person-years of follow-up (incidence rate, 7.6 [95% CI, 6.4-8.9]/100 person-years). Patients with lower eGFRs had a higher frequency of INR ≥ 4 (P<0.001). Risk of hemorrhage was affected significantly by eGFR-INR interaction. At INR<4, there was no difference in hemorrhage risk by eGFR (all P ≥ 0.4). At INR≥4, patients with eGFRs of 30 to 44 and < 30 mL/min/1.73 m(2) had 2.2-fold (95% CI, 0.8-6.1; P=0.1) and 5.8-fold (95% CI, 2.9-11.4; P<0.001) higher hemorrhage risks, respectively, versus those with eGFRs ≥ 60 mL/min/1.73 m(2). In the reversal cohort, 35 (47%) had eGFRs < 45 mL/min/1.73 m(2). Patients with eGFRs < 45 mL/min/1.73 m(2) experienced slower anticoagulation reversal as assessed by INR (P=0.04) and PIVKA-II level (P=0.008) than those with eGFRs ≥ 45 mL/min/1.73 m(2). LIMITATIONS: Limited sample size in the reversal cohort, unavailability of antibiotic use and urine albumin data. CONCLUSIONS: Patients with lower eGFRs have differentially higher hemorrhage risk at INR ≥ 4. Moreover, because the INR reversal rate is slower, hemorrhage risk is prolonged.
BACKGROUND: Anticoagulation management is difficult in chronic kidney disease, with frequent supratherapeutic international normalized ratios (INRs ≥ 4) increasing hemorrhagic risk. We evaluated whether the interaction of INR and lower estimated glomerular filtration rate (eGFR) increases hemorrhage risk and whether patients with lower eGFRs experience slower anticoagulation reversal. STUDY DESIGN: Prospective cohort study. SETTING & PARTICIPANTS: Warfarin pharmacogenetics cohort (1,273 long-term warfarin users); warfarin reversal cohort (74 warfarin users admitted with INRs ≥ 4). PREDICTOR: eGFR, INR as time-dependent covariate, and their interaction in the pharmacogenetics cohort; eGFR in the reversal cohort. OUTCOMES & MEASUREMENTS: In the pharmacogenetics cohort, hemorrhagic (serious, life-threatening, and fatal bleeding) risk was assessed using proportional hazards regression. In the reversal cohort, anticoagulation reversal was assessed from changes in INR, warfarin and metabolite concentrations, clotting factors (II, VII, IX, and X), and PIVKA-II (protein induced by vitamin K absence or antagonist II) levels at presentation and after reversal, using linear regression and path analysis. RESULTS: In the pharmacogenetics cohort, 454 (35.7%) had eGFRs < 60 mL/min/1.73 m(2). There were 137 hemorrhages in 119 patients over 1,802 person-years of follow-up (incidence rate, 7.6 [95% CI, 6.4-8.9]/100 person-years). Patients with lower eGFRs had a higher frequency of INR ≥ 4 (P<0.001). Risk of hemorrhage was affected significantly by eGFR-INR interaction. At INR<4, there was no difference in hemorrhage risk by eGFR (all P ≥ 0.4). At INR≥4, patients with eGFRs of 30 to 44 and < 30 mL/min/1.73 m(2) had 2.2-fold (95% CI, 0.8-6.1; P=0.1) and 5.8-fold (95% CI, 2.9-11.4; P<0.001) higher hemorrhage risks, respectively, versus those with eGFRs ≥ 60 mL/min/1.73 m(2). In the reversal cohort, 35 (47%) had eGFRs < 45 mL/min/1.73 m(2). Patients with eGFRs < 45 mL/min/1.73 m(2) experienced slower anticoagulation reversal as assessed by INR (P=0.04) and PIVKA-II level (P=0.008) than those with eGFRs ≥ 45 mL/min/1.73 m(2). LIMITATIONS: Limited sample size in the reversal cohort, unavailability of antibiotic use and urine albumin data. CONCLUSIONS:Patients with lower eGFRs have differentially higher hemorrhage risk at INR ≥ 4. Moreover, because the INR reversal rate is slower, hemorrhage risk is prolonged.
Authors: Elaine M Hylek; Alan S Go; Yuchiao Chang; Nancy G Jensvold; Lori E Henault; Joe V Selby; Daniel E Singer Journal: N Engl J Med Date: 2003-09-11 Impact factor: 91.245
Authors: Megan V Yanik; Marguerite R Irvin; T Mark Beasley; Pamala A Jacobson; Bruce A Julian; Nita A Limdi Journal: Pharmacotherapy Date: 2017-11-02 Impact factor: 4.705
Authors: K L Cheung; N A Zakai; P W Callas; G Howard; B K Mahmoodi; C A Peralta; S E Judd; M Kurella Tamura; M Cushman Journal: J Thromb Haemost Date: 2018-08-09 Impact factor: 5.824
Authors: Atlas Khan; Michael C Turchin; Amit Patki; Vinodh Srinivasasainagendra; Ning Shang; Rajiv Nadukuru; Alana C Jones; Edyta Malolepsza; Ozan Dikilitas; Iftikhar J Kullo; Daniel J Schaid; Elizabeth Karlson; Tian Ge; James B Meigs; Jordan W Smoller; Christoph Lange; David R Crosslin; Gail P Jarvik; Pavan K Bhatraju; Jacklyn N Hellwege; Paulette Chandler; Laura Rasmussen Torvik; Alex Fedotov; Cong Liu; Christopher Kachulis; Niall Lennon; Noura S Abul-Husn; Judy H Cho; Iuliana Ionita-Laza; Ali G Gharavi; Wendy K Chung; George Hripcsak; Chunhua Weng; Girish Nadkarni; Marguerite R Irvin; Hemant K Tiwari; Eimear E Kenny; Nita A Limdi; Krzysztof Kiryluk Journal: Nat Med Date: 2022-06-16 Impact factor: 87.241
Authors: Brittney H Davis; Rajbeer Sangha; Chrisly Dillon; Todd M Brown; Renuka Narayan; Mark Beasley; Tom McElderry; Thomas D Nolin; Nita A Limdi Journal: Am J Kidney Dis Date: 2020-12-02 Impact factor: 11.072